Vizomet is indicated for the relief of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
DOSAGE AND ADMINISTRATION
A thin film of Vizomet should be applied to the affected skin areas once daily until the lesion heals or for a duration of three weeks, whichever is sooner.
Vizomet is contraindicated in facial rosacea, acne vulgaris, perioral dermatitis, perianal and genital pruritis, napkin eruptions, bacterial (e.g. impetigo), viral (e.g. herpes simplex, herpes zoster and chickenpox) and fungal (e.g. candida or dermatophyte) infections, varicella, tuberculosis, syphilis or post-vaccine reactions. Vizomet should not be used in patients who are sensitive to mometasone furoate, to other corticosteroids or to any components of this preparation.
WARNINGS AND PRECAUTIONS
If irritation or sensitisation develops with the use of mometasone furoate, treatment should be withdrawn and appropriate therapy instituted.
Should an infection develop, use of an appropriate antifungal or antibacterial agent should be instituted. If a favourable response does not occur promptly, the corticosteroid should be discontinued until the infection is adequately controlled.
Local and systemic toxicity is common especially following long continued use on large areas of damaged skin, in flexures and with polythene occlusion. If used in childhood, or on the face, courses should be limited to 5 days and occlusion should not be used. Long term continuous therapy should be avoided in all patients irrespective of age.
Topical steroids may be hazardous in psoriasis for a number of reasons including rebound relapses following development of tolerance, risk of centralised pustular psoriasis and development of local or systemic toxicity due to impaired barrier function of the skin. If used in psoriasis careful patient supervision is important.